Pharma News

The National Institutes of Health plans to end funding to Moderate Alcohol and Cardiovascular Health (MACH) trial. National Institute of Alcohol Abuse and Alcoholism (NIAAA) funding for the MACH trial will end within the next few months following completion of an orderly closeout.

The National Pharmaceutical Pricing Authority (NPPA) has revised retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 in a notification dated 12 June 2018.

The central government has ordered pharmacies to display generic drugs on separate shelves so that consumers can opt for generic medicine to expensive brand name drugs.
Drug Comptroller General has issued a letter to all states and union territories to provide a shelf for display of generic medicines.

WHO Director-General Dr Tedros Adhanom Ghebreyesus is joining Prime Minister António Costa of Portugal to launch the new "WHO Global action plan on physical activity and health 2018-2030: More active people for a healthier world."  Physical inactivity is more than a health challenge: the financial costs are also enormous.

FDA and the USDA announced the alignment of the USDA Harmonized Good Agricultural Practices Audit Program (USDA H-GAP) with the requirements of the FDA Food Safety Modernization Act’s (FSMA’s) Produce Safety Rule.

The U.S. Food and Drug Administration filed a complaint against Innovative BioDefense, Inc. of Lake Forest, California, and Colette Cozean, the company’s president and chief executive officer, to prohibit them from selling Zylast topical antiseptics with claims that they are effective against infection by pathogens such as norovirus, rotavirus, flu virus, Methicillin-Resistant Staphylococcus Aureus (MRSA), and Ebola. Claims that a hand sanitizer can protect consumers against infection from pathogens are drug claims and therefore, these products are regulated by the FDA as drugs. These products from Innovative BioDefense, Inc. have not been proven to be safe and effective for these uses and are not approved by the FDA.

Dug price regulator has directed all importers of medical devices to submit data in proper format.

Now hospitals will register disease of each patient  online. The pharmacist at the drug distribution centre gives medicine to him without putting anything about his disease in the online system.

Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Aimovig, intended for prophylaxis of migraine. The applicant for this medicinal product is Novartis Europharm Limited.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU) for Tegsedi (inotersen), a medicine for treatment of stage 1 or stage 2 polyneuropathy (a condition in which the peripheral nerves are damaged) in patients with hereditary transthyretin amyloidosis (hATTR). This medicine aims to affect the course of the disease and improve quality of life.